A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

NCT00095225 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small-Cell Lung Carcinoma
Neoplasm Recurrence, Local

Interventions

DRUG: Avastin (bevacizumab)
DRUG: Tarceva (erlotinib HCl)

Sponsor

Genentech, Inc.